HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Stada Hints At Further Deals To Come As It Posts Big Sales Rise

Executive Summary

Germany's Stada posts 22% jump in first half sales thanks to recent deals and reveals that more acquisitions may soon follow.

You may also be interested in...

‘Open For Business’ – R&D Partnerships Key To Stada’s Ambitious Growth Strategy

R&D partnerships are key to Stada's ambitious growth strategy, the company's new CHC innovation chief, Steve Makin tells HBW Insight, in the second part of an exclusive interview. CBD and probiotics are particularly exciting areas within the post-COVID wellness/prevention mega-trend, he says, in which Stada is already making headway with new products. 

Stada Grabs GSK Brands In Key EU Markets

Stada says it has become a "major consumer healthcare player" after signing a deal to acquire from GSK 15 brands, which generate annual sales in excess of €100m.

Stada Snaps Up Supplements In Philippines

Stada has added to its consumer healthcare business in the Philippines by acquiring the Fern C range of vitamin C food supplements.

Related Content


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts